FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Vidwans Smruti J.
   2. Issuer Name and Ticker or Trading Symbol
Rennova Health, Inc. [RNVA] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Science Officer
(Last)
(First)
(Middle)
400 S. AUSTRALIAN AVE., SUITE 800		 3. Date of Earliest Transaction (Month/Day/Year)
11/02/2015
(Street)

WEST PALM BEACH, FL 33401		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock               1,000 (1) D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options to Purchase Common Stock $ 4.8 11/02/2015   A   120,000   11/02/2016(2) 11/02/2025 Common Stock 120,000 $ 0 120,000 D  
Options to Purchase Common Stock $ 39.4 07/12/2012   J(3)   3,000   11/02/2015(3) 07/12/2022 Common Stock 3,000 (3) 3,000 D  
Options to Purchase Common Stock $ 7.5 12/08/2014   J(3)   1,000   11/02/2015(3) 12/08/2024 Common Stock 1,000 (3) 1,000 D  
Options to Purchase Common Stock $ 19.9 07/03/2014   J(3)   1,200   11/02/2015(3) 07/03/2024 Common Stock 1,200 (3) 1,200 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Vidwans Smruti J.
400 S. AUSTRALIAN AVE., SUITE 800
WEST PALM BEACH, FL 33401		       Chief Science Officer  

Signatures

 /s/ Smruti Vidwans   11/30/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Reflects the one-for-ten reverse stock split effectuated by Rennova Health, Inc. ("Rennova").
(2) The Option shall vest with respect to fifty percent (50%) of the total number of shares of Common Stock (the "Shares") subject to the Option on the six-month anniversary of the date of grant, and the remaining fifty percent (50%) of the total number of Shares subject to the Option on the twelve-month anniversary, subject to the Reporting Person's continued status as an employee on each applicable vesting date, such that all Shares subject to the Option shall be fully vested on the first anniversary of the date of grant of the Option.
(3) In connection with the merger transaction with Medytox Solutions, Inc., and the one-for-ten reverse stock split effectuated by Rennova, the Options, which were previously reported, have been adjusted to reflect accelerated vesting; an adjustment to the number of Options and the number of shares of common stock issuable upon exercise of the Options; and an adjustment to the exercise price as a consequence of the reverse split.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.